CD163 and cancer: Within the tumor microenvironment, M2 cytokines, including IL-4, IL-13, and IL-10, are present, and TAMs in various cancer models exhibit an M2 activation profile characterized by increased expression of CD163, MRC-1, C-type lectins, IL-10, and Arg-1, as well as reduced production of IL-12 [161–166].